Adaptimmune (ADAP)

Adaptimmune

The time to redefine the treatment of cancer is now.

About Us

Redefining the treatment of solid tumor cancers.

Adaptimmune is committed to treating the most challenging solid tumors using a proprietary cell therapy platform that harnesses a patient's cells to combat their cancer.

Using a personalized approach that has the potential to radically improve the patient experience.

We use cell therapy, a promising yet complex area of science, to engineer a person’s own cells to fight cancer.

A future where a single infusion could reshape cancer care.

We are a fully integrated company on the verge of a new era. With our first BLA submitted to the FDA, we are aiming to commercialize the  first engineered T-cell therapy in solid tumors to help improve cancer treatment.

SEC Filings

For all investor or media inquiries, visit https://www.adaptimmune.com/contact.

Filing date	Description	Form	Filing Group	View
May 13, 2021	Quarterly report which provides a continuing view of a company's financial position	10-Q	Quarterly Filings	0001564590-21-027203.pdf 0001564590-21-027203.rtf 0001564590-21-027203.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
Apr 30, 2021	Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3	424B5	Registration Statements	0001193125-21-145133.pdf 0001193125-21-145133.rtf View HTML
Apr 30, 2021	Report of unscheduled material events or corporate event	8-K	Current Reports	0001193125-21-145158.pdf 0001193125-21-145158.rtf 0001193125-21-145158.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
Apr 02, 2021	Statement of changes in beneficial ownership of securities	4	3,4,5	0001209191-21-024608.pdf 0001209191-21-024608.rtf 0001209191-21-024608.xls View HTML
Mar 29, 2021	Report of unscheduled material events or corporate event	8-K	Current Reports	0001564590-21-015964.pdf 0001564590-21-015964.rtf 0001564590-21-015964.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
Mar 16, 2021	Annual report which provides a comprehensive overview of the company for the past year	10-K	Annual Filings	0001564590-21-013563.pdf 0001564590-21-013563.rtf 0001564590-21-013563.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
Mar 16, 2021	Securities offered to employees pursuant to employee benefit plans	S-8	Registration Statements	0001193125-21-082933.pdf 0001193125-21-082933.rtf 0001193125-21-082933.xls View HTML
Mar 16, 2021	S-3ASR	S-3ASR	Registration Statements	0001193125-21-082946.pdf 0001193125-21-082946.rtf 0001193125-21-082946.xls View HTML
Mar 11, 2021	Report of unscheduled material events or corporate event	8-K	Current Reports	0001564590-21-012228.pdf 0001564590-21-012228.rtf 0001564590-21-012228.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
Mar 08, 2021	Statement of changes in beneficial ownership of securities	4	3,4,5	0000899243-21-010268.pdf 0000899243-21-010268.rtf 0000899243-21-010268.xls View HTML

Data provided by Kaleidoscope.

Adaptimmune (ADAP)

Adaptimmune

The time to redefine the treatment of cancer is now.

About Us

Redefining the treatment of solid tumor cancers.

Adaptimmune is committed to treating the most challenging solid tumors using a proprietary cell therapy platform that harnesses a patient's cells to combat their cancer.

Using a personalized approach that has the potential to radically improve the patient experience.

We use cell therapy, a promising yet complex area of science, to engineer a person’s own cells to fight cancer.

A future where a single infusion could reshape cancer care.

We are a fully integrated company on the verge of a new era. With our first BLA submitted to the FDA, we are aiming to commercialize the  first engineered T-cell therapy in solid tumors to help improve cancer treatment.